Back To Search Results

Beta Blockers

Editor: Arif Jan Updated: 8/22/2023 10:54:04 AM


Beta-blockers, as a class of drugs, are primarily used to treat cardiovascular diseases and other conditions.[1]

Beta receptors exist in three distinct forms: beta-1 (B1), beta-2 (B2), and beta-3 (B3). Beta-1 receptors located primarily in the heart mediate cardiac activity. Beta-2 receptors, with their diverse location in many organ systems, control various aspects of metabolic activity and induce smooth muscle relaxation. Beta-3 receptors induce the breakdown of fat cells and are less clinically relevant at present. Blockade of these receptors by beta-blocking medicines is used to treat a broad range of illnesses.[1] Beta-blockers, as a class of medications, are essential drugs and are first-line treatments in many acute and chronic conditions.

Beta-blockers are indicated and have FDA approval for the treatment of tachycardia, hypertension, myocardial infarction, congestive heart failure, cardiac arrhythmias, coronary artery disease, hyperthyroidism, essential tremor, aortic dissection, portal hypertension, glaucoma, migraine prophylaxis, and other conditions. They are also used to treat less common conditions such as long QT syndrome and hypertrophic obstructive cardiomyopathy. Beta-blockers are available for administration in three primary forms: oral, intravenous, and ophthalmic, and the route of administration often depends on the acuity of the illness (parenteral use in arrhythmias), disease type (topical use in glaucoma) and chronicity of the disease. 

Congestive heart failure patients are treated with beta-blockers if they are in a compensated state. Specifically, the beta-blockers bisoprolol, carvedilol, and metoprolol succinate are the agents chosen. Metoprolol tartrate is not indicated for heart failure and is instead used for other conditions, such as atrial fibrillation. 

Athletes and musicians may use beta-blockers for their anxiolytic effects as well as their inhibitory effects on the sympathetic nervous system. They are not FDA-approved for the treatment of anxiety-related disorders; however, they have a potent anxiolytic effect. Combined with a reduction in tremors, they may lead to improved stage performance. An example of a beta blocker that is commonly prescribed for anxiety or stage fright is propranolol; it may reduce some peripheral symptoms of anxiety, such as tachycardia, sweating, and general tension.[2]

Certain beta blockers are also used specifically in inpatient units rather than for outpatient prescriptions. A common example is esmolol, which is typically used either in the intensive care unit or a cardiac inpatient unit. It is generally used for refractory tachycardia, such as atrial fibrillation, and is titrable given its short onset of action and short half-life. It may also play a role in refractory ventricular tachycardia, which is also known as an electrical storm. 

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

The catecholamines, epinephrine, and norepinephrine bind to B1 receptors and increase cardiac automaticity as well as conduction velocity. B1 receptors also induce renin release, and this leads to an increase in blood pressure. In contrast, binding to B2 receptors causes relaxation of the smooth muscles along with increased metabolic effects such as glycogenolysis.

Beta-blockers vary in their specificity towards different receptors, and accordingly, the effects produced depend on the type of receptor(s) blocked as well as the organ system involved. Some beta-blockers also bind to alpha receptors to some degree, allowing them to induce a different clinical outcome when used in specific settings.

Once beta-blockers bind to the B1 and B2 receptors, they inhibit these effects. Therefore, the chronotropic and inotropic effects on the heart undergo inhibition, and the heart rate slows down as a result. Beta-blockers also decrease blood pressure via several mechanisms, including decreased renin and reduced cardiac output. The negative chronotropic and inotropic effects lead to a decreased oxygen demand; that is how angina improves after beta-blocker usage. These medications also prolong the atrial refractory periods and have a potent antiarrhythmic effect.

Beta-blockers classify as either non-selective or beta-1 selective. There are also beta-blocking drugs that affect both beta-2 and/or beta-3 selectively; neither has a known clinical purpose to date. Non-selective agents bind to both beta-1 and beta-2 receptors and induce antagonizing effects via both receptors. Examples include propranolol, carvedilol, sotalol, and labetalol. Beta-1 receptor-selective blockers like atenolol, bisoprolol, metoprolol, and esmolol only bind to the beta-1 receptors; therefore, they are cardio-selective.[3][4][5]

Beta-blockers lower the secretion of melatonin and hence may cause insomnia and sleep changes in some patients.[6]

Alpha-1 receptors induce vasoconstriction and increased cardiac chronotropy; this means agonism at the alpha-1 receptors leads to higher blood pressure and an increased heart rate. In contrast, antagonism at the alpha-1 receptor leads to vasodilation and negative chronotropic, which leads to lower blood pressure and decreased heart rate. Some beta-blockers, such as carvedilol, labetalol, and bucindolol, have additional alpha-1 receptor blockage activity in addition to their non-selective beta receptor blockage. This property is clinically useful because beta-blockers that block the alpha-1 receptor have a more pronounced clinical effect on treating hypertension.[7]

Sotalol is a beta blocker and also blocks potassium channels. It is a class III antiarrhythmic. 


Beta-blockers are available in oral, intravenous, or ophthalmic forms and are also injectable intramuscularly.

Dosages are available in various ranges, depending on the specific medication. Outpatient prescriptions may include once-a-day dosing for longer-acting beta-blockers, such as metoprolol succinate. However, most beta blockers are often dosed at least twice per day. Certain beta-blockers, such as propranolol, with a half-life of approximately 4 hours, are dosed up to 3 or 4 times a day, depending on the indication and dose.

Adverse Effects

Beta receptors are found all over the body and induce a broad range of physiologic effects. The blockade of these receptors with beta-blocker medications can lead to many adverse effects. Bradycardia and hypotension are two adverse effects that may commonly occur. Fatigue, dizziness, nausea, and constipation are also widely reported. Some patients report sexual dysfunction and erectile dysfunction.

Less commonly, bronchospasm presents in patients on beta-blockers. Asthmatic patients are at a higher risk.[8] Patients with Raynaud syndrome are also at risk of exacerbation. Beta-blockers can induce hyperglycemia and mask the hemodynamic signs usually seen in a hypoglycemic patient, such as tachycardia.

Some patients report insomnia, sleep changes, and nightmares while using beta-blockers. This effect is more pronounced with beta-blockers that cross the blood-brain barrier. Some patients can experience fatigue or weight gain while on beta blockers. Managing these adverse events involves discontinuing the medication. Certain beta blockers are more likely to induce weight gain or fatigue. 

Carvedilol may increase edema in some patients.[9]

Sotalol blocks the potassium channels in the heart and thereby induces QT prolongation. It increases the risk of torsades de pointes.[10]

All beta-blockers, especially in patients with cardiac risk factors, carry a risk of heart block.


Traditionally, beta-blockers have been contraindicated in asthmatic patients. However, recommendations have aligned for allowing cardio-selective beta-blockers, also known as beta-1 selective, in asthmatics but not non-selective beta-blockers. Non-selective beta-blockers should not be used in patients with asthma.

Patients who have either acute or chronic bradycardia and/or hypotension have relative contraindications to beta-blocker usage. 

Specific beta-blockers are contraindicated depending on the patient's past medical history. Patients diagnosed with long QT syndrome or who have had torsades de pointes in the past should not use the drug sotalol. Patients with the Raynaud phenomenon should avoid beta-blockers due to the risk of exacerbation.[11][10]


The patient's heart rate and blood pressure require monitoring while using beta-blockers. When using sotalol, the clinician must monitor the QTc interval as sotalol has QT-prolonging effects.[12] Other side effects, such as fatigue and weight gain, can also occur with outpatient beta-blocker use. 


The antidote for beta-blocker overdose is glucagon. It is especially useful in beta-blocker-induced cardiotoxicity. The second line of treatment is cardiac pacing if glucagon fails, and this may include transcutaneous pacing or transvenous pacing. 

Potential acute toxicity can be mitigated by using extended-release formulations as a preventative strategy, which will delay peak toxicity.[13]

Enhancing Healthcare Team Outcomes

Beta-blockers are a broad class of medications that are used for various clinical benefits but also carry the potential for adverse effects. They are prescribed by clinicians (MDs, DOs, NPs, or PAs) in both outpatient and inpatient settings, largely for the treatment of cardiovascular-related illnesses. When a patient is admitted to an inpatient ward, monitoring the clinical effects and potential adverse effects is an interprofessional task. This is crucial because excessively high serum levels can have serious or even fatal consequences.

Nurses will generally be the first caregivers to take note of any unwanted effects, such as a change in vital signs. In contrast, outpatient settings differ in that the pharmacist may be the closest line of healthcare contact for a patient. The pharmacist will dispense the medication, perform medication reconciliation, verify dosing, and also advise other interprofessional team members and the patient of any potential adverse effects. It is also imperative to take note of any patients who are currently on beta-blockers, as it provides a clinical context for potential symptoms. Many clinical trials have been conducted on beta-blockers and shown to prolong life in patients with cardiovascular disease.[14][15][16] [Level 2]

The interprofessional healthcare team needs to prescribe, manage, and monitor the use of beta-blockers safely and effectively. [Level 5]



do Vale GT, Ceron CS, Gonzaga NA, Simplicio JA, Padovan JC. Three Generations of β-blockers: History, Class Differences and Clinical Applicability. Current hypertension reviews. 2019:15(1):22-31. doi: 10.2174/1573402114666180918102735. Epub     [PubMed PMID: 30227820]


Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. Journal of psychopharmacology (Oxford, England). 2016 Feb:30(2):128-39. doi: 10.1177/0269881115612236. Epub 2015 Oct 20     [PubMed PMID: 26487439]

Level 1 (high-level) evidence


Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta cardiologica. 2010 Oct:65(5):565-70     [PubMed PMID: 21125979]


Rehsia NS, Dhalla NS. Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. Experimental and clinical cardiology. 2010 Winter:15(4):e86-95     [PubMed PMID: 21264074]


Machackova J, Sanganalmath SK, Elimban V, Dhalla NS. β-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure. Journal of cellular and molecular medicine. 2011 Mar:15(3):545-54. doi: 10.1111/j.1582-4934.2010.01015.x. Epub     [PubMed PMID: 20082655]

Level 3 (low-level) evidence


Fares A. Night-time exogenous melatonin administration may be a beneficial treatment for sleeping disorders in beta blocker patients. Journal of cardiovascular disease research. 2011 Jul:2(3):153-5. doi: 10.4103/0975-3583.85261. Epub     [PubMed PMID: 22022142]


Weir MR. Beta-blockers in the treatment of hypertension: are there clinically relevant differences? Postgraduate medicine. 2009 May:121(3):90-8. doi: 10.3810/pgm.2009.05.2007. Epub     [PubMed PMID: 19491545]


Marques de Mello L, Cruz ÁA. A proposed scheme to cope with comorbidities in asthma. Pulmonary pharmacology & therapeutics. 2018 Oct:52():41-51. doi: 10.1016/j.pupt.2018.08.005. Epub 2018 Aug 25     [PubMed PMID: 30149069]


Soma K, Yao A, Saito A, Inaba T, Ishikawa Y, Hirata Y, Komuro I. Regular Treatment Strategy with a Large Amount of Carvedilol for Heart Failure Improves Biventricular Systolic Failure in a Patient with Repaired Tetralogy of Fallot. International heart journal. 2018 Sep 26:59(5):1169-1173. doi: 10.1536/ihj.17-525. Epub 2018 Aug 11     [PubMed PMID: 30101848]


Etchegoyen CV, Keller GA, Mrad S, Cheng S, Di Girolamo G. Drug-induced QT Interval Prolongation in the Intensive Care Unit. Current clinical pharmacology. 2017:12(4):210-222. doi: 10.2174/1574884713666180223123947. Epub     [PubMed PMID: 29473523]


De Vecchis R, Ariano C, Di Biase G, Noutsias M. Acquired drug-induced long QTc: new insights coming from a retrospective study. European journal of clinical pharmacology. 2018 Dec:74(12):1645-1651. doi: 10.1007/s00228-018-2537-y. Epub 2018 Aug 15     [PubMed PMID: 30112668]

Level 2 (mid-level) evidence


Farzam K, Tivakaran VS. QT Prolonging Drugs. StatPearls. 2023 Jan:():     [PubMed PMID: 30521285]


Graudins A, Lee HM, Druda D. Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies. British journal of clinical pharmacology. 2016 Mar:81(3):453-61. doi: 10.1111/bcp.12763. Epub 2015 Oct 30     [PubMed PMID: 26344579]


Hoedemaker NP, Roolvink V, de Winter RJ, van Royen N, Fuster V, García-Ruiz JM, Er F, Gassanov N, Hanada K, Okumura K, Ibáñez B, van 't Hof AW, Damman P. Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A patient-pooled meta-analysis of randomized clinical trials. European heart journal. Acute cardiovascular care. 2020 Aug:9(5):469-477. doi: 10.1177/2048872619830609. Epub 2019 Feb 14     [PubMed PMID: 30759994]

Level 1 (high-level) evidence


Suissa S, Ernst P. Beta-Blockers in COPD: A Methodological Review of the Observational Studies. COPD. 2018 Oct:15(5):520-525. doi: 10.1080/15412555.2018.1554637. Epub     [PubMed PMID: 30822238]


Jensen MT. Resting heart rate and relation to disease and longevity: past, present and future. Scandinavian journal of clinical and laboratory investigation. 2019 Feb-Apr:79(1-2):108-116. doi: 10.1080/00365513.2019.1566567. Epub 2019 Feb 14     [PubMed PMID: 30761923]